Published in Mol Immunol on July 14, 2005
Glomeruli of Dense Deposit Disease contain components of the alternative and terminal complement pathway. Kidney Int (2009) 3.12
Spontaneous hemolytic uremic syndrome triggered by complement factor H lacking surface recognition domains. J Exp Med (2007) 2.55
Translational mini-review series on complement factor H: renal diseases associated with complement factor H: novel insights from humans and animals. Clin Exp Immunol (2008) 1.89
Structure of complement factor H carboxyl-terminus reveals molecular basis of atypical haemolytic uremic syndrome. EMBO J (2006) 1.72
A novel targeted inhibitor of the alternative pathway of complement and its therapeutic application in ischemia/reperfusion injury. J Immunol (2008) 1.70
Mutations of factor H impair regulation of surface-bound C3b by three mechanisms in atypical hemolytic uremic syndrome. J Biol Chem (2009) 1.21
Complement regulator Factor H mediates a two-step uptake of Streptococcus pneumoniae by human cells. J Biol Chem (2010) 1.13
Species-specific interaction of Streptococcus pneumoniae with human complement factor H. J Immunol (2008) 1.08
Lyme borreliosis spirochete Erp proteins, their known host ligands, and potential roles in mammalian infection. Int J Med Microbiol (2008) 1.00
Two factor H-related proteins from the mouse: expression analysis and functional characterization. Immunogenetics (2006) 0.87
Essential role of surface-bound complement factor H in controlling immune complex-induced arthritis. J Immunol (2013) 0.87
Deletion of Crry and DAF on murine platelets stimulates thrombopoiesis and increases factor H-dependent resistance of peripheral platelets to complement attack. J Immunol (2013) 0.80
An extended mini-complement factor H molecule ameliorates experimental C3 glomerulopathy. Kidney Int (2015) 0.80
Novel bifunctional single-chain variable antibody fragments to enhance virolysis by complement: generation and proof-of-concept. Biomed Res Int (2014) 0.75
The Murine Factor H-Related Protein FHR-B Promotes Complement Activation. Front Immunol (2017) 0.75
Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. Clin J Am Soc Nephrol (2010) 3.82
Membranoproliferative glomerulonephritis type II (dense deposit disease): an update. J Am Soc Nephrol (2005) 3.57
Glomeruli of Dense Deposit Disease contain components of the alternative and terminal complement pathway. Kidney Int (2009) 3.12
New approaches to the treatment of dense deposit disease. J Am Soc Nephrol (2007) 3.02
Factor H-related protein 1 (CFHR-1) inhibits complement C5 convertase activity and terminal complex formation. Blood (2009) 2.97
Mutations in factor H reduce binding affinity to C3b and heparin and surface attachment to endothelial cells in hemolytic uremic syndrome. J Clin Invest (2003) 2.96
Complement factor H binds malondialdehyde epitopes and protects from oxidative stress. Nature (2011) 2.64
Factor H autoantibodies in atypical hemolytic uremic syndrome correlate with CFHR1/CFHR3 deficiency. Blood (2007) 2.46
Monkey malaria in a European traveler returning from Malaysia. Emerg Infect Dis (2008) 2.32
Review of cases with the emerging fifth human malaria parasite, Plasmodium knowlesi. Clin Infect Dis (2011) 2.14
Complement inhibitor factor H binding to Lyme disease spirochetes is mediated by inducible expression of multiple plasmid-encoded outer surface protein E paralogs. J Immunol (2002) 2.06
Factor H family proteins and human diseases. Trends Immunol (2008) 2.02
Successful treatment of DEAP-HUS with eculizumab. Pediatr Nephrol (2013) 2.00
Y402H polymorphism of complement factor H affects binding affinity to C-reactive protein. J Immunol (2007) 2.00
Complement resistance of Borrelia burgdorferi correlates with the expression of BbCRASP-1, a novel linear plasmid-encoded surface protein that interacts with human factor H and FHL-1 and is unrelated to Erp proteins. J Biol Chem (2003) 1.99
An imbalance of human complement regulatory proteins CFHR1, CFHR3 and factor H influences risk for age-related macular degeneration (AMD). Hum Mol Genet (2010) 1.95
Factor H dysfunction in patients with atypical hemolytic uremic syndrome contributes to complement deposition on platelets and their activation. Blood (2008) 1.95
Defective complement control of factor H (Y402H) and FHL-1 in age-related macular degeneration. Mol Immunol (2007) 1.94
Streptococcus pneumoniae evades complement attack and opsonophagocytosis by expressing the pspC locus-encoded Hic protein that binds to short consensus repeats 8-11 of factor H. J Immunol (2002) 1.87
A common site within factor H SCR 7 responsible for binding heparin, C-reactive protein and streptococcal M protein. Eur J Immunol (2003) 1.77
Tumor necrosis factor alpha enhances influenza A virus-induced expression of antiviral cytokines by activating RIG-I gene expression. J Virol (2006) 1.75
Immune evasion of the human pathogen Pseudomonas aeruginosa: elongation factor Tuf is a factor H and plasminogen binding protein. J Immunol (2007) 1.74
Structure of complement factor H carboxyl-terminus reveals molecular basis of atypical haemolytic uremic syndrome. EMBO J (2006) 1.72
Anti factor H autoantibodies block C-terminal recognition function of factor H in hemolytic uremic syndrome. Blood (2007) 1.70
Complement inhibitor eculizumab in atypical hemolytic uremic syndrome. Clin J Am Soc Nephrol (2009) 1.70
Association between complement factor H and proteoglycans in early human coronary atherosclerotic lesions: implications for local regulation of complement activation. Arterioscler Thromb Vasc Biol (2003) 1.68
IFN-alpha enhances TLR3-mediated antiviral cytokine expression in human endothelial and epithelial cells by up-regulating TLR3 expression. J Immunol (2005) 1.67
Platelet-associated complement factor H in healthy persons and patients with atypical HUS. Blood (2009) 1.67
Suicidal death of erythrocytes in recurrent hemolytic uremic syndrome. J Mol Med (Berl) (2006) 1.62
Factor H and atypical hemolytic uremic syndrome: mutations in the C-terminus cause structural changes and defective recognition functions. J Am Soc Nephrol (2005) 1.62
LfhA, a novel factor H-binding protein of Leptospira interrogans. Infect Immun (2006) 1.61
C3 deposition glomerulopathy due to a functional factor H defect. Kidney Int (2008) 1.61
The interactive Factor H-atypical hemolytic uremic syndrome mutation database and website: update and integration of membrane cofactor protein and Factor I mutations with structural models. Hum Mutat (2007) 1.59
Dual interaction of factor H with C3d and glycosaminoglycans in host-nonhost discrimination by complement. Proc Natl Acad Sci U S A (2011) 1.58
The host immune regulator factor H interacts via two contact sites with the PspC protein of Streptococcus pneumoniae and mediates adhesion to host epithelial cells. J Immunol (2007) 1.58
Glycerol-3-phosphate dehydrogenase 2 is a novel factor H-, factor H-like protein 1-, and plasminogen-binding surface protein of Candida albicans. J Infect Dis (2012) 1.58
Complement resistance mechanisms of streptococci. Mol Immunol (2003) 1.56
Neisserial lipooligosaccharide is a target for complement component C4b. Inner core phosphoethanolamine residues define C4b linkage specificity. J Biol Chem (2003) 1.55
De novo gene conversion in the RCA gene cluster (1q32) causes mutations in complement factor H associated with atypical hemolytic uremic syndrome. Hum Mutat (2006) 1.46
Immune evasion of Borrelia burgdorferi: mapping of a complement-inhibitor factor H-binding site of BbCRASP-3, a novel member of the Erp protein family. Eur J Immunol (2003) 1.45
Upstream conserved sequences of mouse leukemia viruses are important for high transgene expression in lymphoid and hematopoietic cells. Mol Ther (2002) 1.44
Functional characterization of BbCRASP-2, a distinct outer membrane protein of Borrelia burgdorferi that binds host complement regulators factor H and FHL-1. Mol Microbiol (2006) 1.43
Complement regulator-acquiring surface protein 1 imparts resistance to human serum in Borrelia burgdorferi. J Immunol (2005) 1.42
Binding of complement factor H to endothelial cells is mediated by the carboxy-terminal glycosaminoglycan binding site. Am J Pathol (2005) 1.40
Combination of factor H mutation and properdin deficiency causes severe C3 glomerulonephritis. J Am Soc Nephrol (2012) 1.40
Binding of the complement inhibitor C4bp to serogroup B Neisseria meningitidis. J Immunol (2005) 1.38
Mutations in FN1 cause glomerulopathy with fibronectin deposits. Proc Natl Acad Sci U S A (2008) 1.37
Yersinia enterocolitica serum resistance proteins YadA and ail bind the complement regulator C4b-binding protein. PLoS Pathog (2008) 1.36
Early growth response proteins (EGR) and nuclear factors of activated T cells (NFAT) form heterodimers and regulate proinflammatory cytokine gene expression. Nucleic Acids Res (2003) 1.36
The Staphylococcus aureus protein Sbi acts as a complement inhibitor and forms a tripartite complex with host complement Factor H and C3b. PLoS Pathog (2008) 1.34
Comparative and functional genomics provide insights into the pathogenicity of dermatophytic fungi. Genome Biol (2011) 1.34
Streptococcus pneumoniae capsular serotype 19F is more resistant to C3 deposition and less sensitive to opsonophagocytosis than serotype 6B. Infect Immun (2008) 1.33
Complement C3b/C3d and cell surface polyanions are recognized by overlapping binding sites on the most carboxyl-terminal domain of complement factor H. J Immunol (2002) 1.32
The complement factor H R1210C mutation is associated with atypical hemolytic uremic syndrome. J Am Soc Nephrol (2008) 1.31
Borrelia burgdorferi infection-associated surface proteins ErpP, ErpA, and ErpC bind human plasminogen. Infect Immun (2008) 1.27
Identification and functional characterization of complement regulator-acquiring surface protein 1 of the Lyme disease spirochetes Borrelia afzelii and Borrelia garinii. Infect Immun (2005) 1.27
Autoantibodies in haemolytic uraemic syndrome (HUS). Thromb Haemost (2009) 1.27
Binding of the long pentraxin PTX3 to factor H: interacting domains and function in the regulation of complement activation. J Immunol (2008) 1.23
Where next with atypical hemolytic uremic syndrome? Mol Immunol (2007) 1.23
Successful plasma therapy for atypical hemolytic uremic syndrome caused by factor H deficiency owing to a novel mutation in the complement cofactor protein domain 15. Am J Kidney Dis (2005) 1.21
Mutations of factor H impair regulation of surface-bound C3b by three mechanisms in atypical hemolytic uremic syndrome. J Biol Chem (2009) 1.21
Regulation of complement activation at the C3-level by serum resistant leptospires. Microb Pathog (2005) 1.21
Lysine-dependent multipoint binding of the Borrelia burgdorferi virulence factor outer surface protein E to the C terminus of factor H. J Immunol (2004) 1.20
Immunological characterization of the complement regulator factor H-binding CRASP and Erp proteins of Borrelia burgdorferi. Int J Med Microbiol (2004) 1.18
Clinical isolates of Streptococcus pneumoniae bind the complement inhibitor C4b-binding protein in a PspC allele-dependent fashion. J Immunol (2009) 1.18
Plasminogen is a complement inhibitor. J Biol Chem (2012) 1.17
Nontypeable Haemophilus influenzae protein E binds vitronectin and is important for serum resistance. J Immunol (2009) 1.17
Binding of human factor H-related protein 1 to serum-resistant Borrelia burgdorferi is mediated by borrelial complement regulator-acquiring surface proteins. J Infect Dis (2007) 1.17
Interaction of phagocytes with filamentous fungi. Curr Opin Microbiol (2010) 1.17
Leptospiral endostatin-like protein A is a bacterial cell surface receptor for human plasminogen. Infect Immun (2010) 1.16
An interactive web database of factor H-associated hemolytic uremic syndrome mutations: insights into the structural consequences of disease-associated mutations. Hum Mutat (2006) 1.16
A case of a diffuse large B-cell lymphoma of plasmablastic type associated with the t(2;5)(p23;q35) chromosome translocation. Am J Surg Pathol (2003) 1.15
The C-terminus of complement factor H is essential for host cell protection. Mol Immunol (2007) 1.14